source
- Amylyx reports positive pivotal trial results for drug targeting post-bariatric hypoglycemiaAmylyx announced that its experimental therapy achieved statistically significant improvement in patients who experience severe hypoglycemia after bariatric surgery. The company said the pivotal t…
- Leo Pharma signs $435 million deal with Tanabe for rare skin disease drug dersimelagonLeo Pharma announced a licensing agreement with Mitsubishi Tanabe Pharma for worldwide rights to dersimelagon, an oral melanocortin-1 receptor agonist targeting rare genetic skin disorders. The dr…